Organovo (ONVO) Given Daily Media Sentiment Score of 0.06

Media headlines about Organovo (NASDAQ:ONVO) have trended somewhat positive on Sunday, Accern reports. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Organovo earned a media sentiment score of 0.06 on Accern’s scale. Accern also gave news coverage about the medical research company an impact score of 44.8706211579219 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:

Separately, Zacks Investment Research lowered Organovo from a “buy” rating to a “hold” rating in a research report on Saturday, February 17th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company’s stock. Organovo presently has an average rating of “Hold” and a consensus target price of $3.40.

Shares of NASDAQ ONVO traded up $0.02 during mid-day trading on Friday, hitting $0.96. 854,494 shares of the stock traded hands, compared to its average volume of 743,207. Organovo has a 52 week low of $0.91 and a 52 week high of $3.19. The firm has a market capitalization of $106.89, a PE ratio of -2.47 and a beta of 2.77.

Organovo (NASDAQ:ONVO) last released its quarterly earnings results on Thursday, February 8th. The medical research company reported ($0.07) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.02. Organovo had a negative return on equity of 69.03% and a negative net margin of 881.93%. The company had revenue of $1.15 million for the quarter, compared to analyst estimates of $1.25 million. During the same period in the previous year, the company posted ($0.09) earnings per share. The firm’s revenue was up .0% on a year-over-year basis. research analysts predict that Organovo will post -0.33 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This article was first posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://www.tickerreport.com/banking-finance/3341648/organovo-onvo-given-daily-media-sentiment-score-of-0-06.html.

Organovo Company Profile

Organovo Holdings, Inc is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.

Insider Buying and Selling by Quarter for Organovo (NASDAQ:ONVO)

Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Zacks: Brokerages Expect PotlatchDeltic  to Post $0.67 EPS
Zacks: Brokerages Expect PotlatchDeltic to Post $0.67 EPS
Zacks: Brokerages Expect BioCryst Pharmaceuticals  Will Announce Quarterly Sales of $10.20 Million
Zacks: Brokerages Expect BioCryst Pharmaceuticals Will Announce Quarterly Sales of $10.20 Million
Virtacoinplus  Price Up 175% Over Last Week
Virtacoinplus Price Up 175% Over Last Week
Sumokoin Tops One Day Trading Volume of $76,838.00
Sumokoin Tops One Day Trading Volume of $76,838.00
Entegris  Updates Q2 Earnings Guidance
Entegris Updates Q2 Earnings Guidance
PCM  Releases Quarterly  Earnings Results, Beats Estimates By $0.05 EPS
PCM Releases Quarterly Earnings Results, Beats Estimates By $0.05 EPS


© 2006-2018 Ticker Report. Google+.